Broncho-munal, capsules 7 mg 10 pcs

ATX code: L03AX.
Pharmacotherapeutic group: immunostimulant.
Nosological classification: ICD-10

Pharmacological properties

Pharmacodynamics
Broncho-Munal® has an immune stimulating effect by strengthening the immunity against bacteria and viruses, respiratory tract infections.
After taking the capsule the bacterial lysate accumulates in the peyer’s plaques of the gastrointestinal mucosa, in particular those located in the small intestine. Antigen-presenting cells in the peyer plaques are activated by the bacterial lysate and subsequently stimulate other cell types (B-lymphocytes) responsible for specific immunity.

This leads to an increase in circulating B-lymphocytes, which leads to increased production of polyclonal antibodies, especially serum IgG and IgA, secreted by the respiratory tract mucosa and salivary glands.

The drug also affects non-specific immunity by stimulating leukocytes, characterized by increase of myeloid and lymphoid cells number and selective increase of receptors expression on their surface.

Clinically Broncho-Munal® reduces the frequency of acute respiratory tract infections, reduces the duration of their course, reduces the likelihood of exacerbations of chronic bronchitis, and also increases the body’s resistance to infections of the respiratory system. It also reduces the need to use other medications, especially antibiotics.

Indications

Broncho-Munal® is used:
• as part of complex therapy of acute respiratory tract infections;
• for the prevention of recurrent respiratory tract infections and exacerbations of chronic bronchitis.

Pharmacological effect

ATX code: L03AX.
Pharmacotherapeutic group: immunostimulating agent.
Nosological classification: ICD-10

Pharmacological properties

Pharmacodynamics
The drug Broncho-Munal® has an immunostimulating effect, strengthening immunity against bacteria and viruses, respiratory tract infections.
After taking the capsule, the bacterial lysate accumulates in Peyer’s patches of the mucous membrane of the gastrointestinal tract, in particular located in the small intestine. Antigen-presenting cells in Peyer’s patches are activated by the bacterial lysate and subsequently stimulate other types of cells (B lymphocytes) responsible for specific immunity.

This leads to an increase in the number of circulating B lymphocytes, which leads to an increase in the production of polyclonal antibodies, especially serum IgG and IgA, secreted by the mucous membrane of the respiratory tract and salivary glands.

The drug also has an effect on nonspecific immunity, stimulating leukocytes, which is characterized by an increase in the number of myeloid and lymphoid cells, as well as a selective increase in the expression of receptors on their surface.

Clinically, Broncho-Munal® reduces the frequency of acute respiratory tract infections, shortens the duration of their course, reduces the likelihood of exacerbations of chronic bronchitis, and also increases the body’s resistance to respiratory system infections. This reduces the need to use other medications, especially antibiotics.

Special instructions

Manifestations of hypersensitivity reactions to the drug are possible. In case of persistent gastrointestinal disorders, skin reactions, respiratory problems or other symptoms of drug intolerance, discontinue the drug and consult a doctor.

The drug does not affect the ability to concentrate and control vehicles and machinery.

Active ingredient

Bacterial lysates

Active components

Bacterial lysates

Composition

1 capsule contains:

Active ingredient:
• bacterial lysates in the form of a standardized bacterial lyophilisate (OM-85) (OM-Pharma, Switzerland) – 7,000 mg:
• Haemophilus influenzae
• Streptococcus pneumoniae
• Streptococcus viridans
• Streptococcus pyogenes
• Klebsiella pneumoniae
• Klebsiella ozaenae
• Staphylococcus aureus
• Moraxella catarrhalis

Excipients:
• propyl gallate (anhydrous)
• sodium glutamate (anhydrous)
• mannitol (as part of the active ingredient)
• magnesium stearate
• pregelatinized starch
• mannitol
Capsule shell:
• indigotine E132
• titanium dioxide E171
• gelatin

Contraindications

• hypersensitivity to the components of the drug;
• pregnancy;
• breastfeeding period;
• children under 12 years of age (children from 6 months to 12 years of age are recommended to take the drug Broncho-Munal® P, 3.5 mg capsules).

Side Effects

Broncho-Munal® is usually well tolerated. Most adverse reactions are classified into the general category with moderate or moderate-severe severity. The most common side effects are gastrointestinal upset, skin reactions and respiratory problems.

According to the World Health Organization (WHO), adverse effects are classified according to their frequency as follows:
• very often (≥ 1/10);
• often (≥ 1/100, < 1/10);
• uncommon (≥ 1/1000, < 1/100);
• rare (≥ 1/10000, < 1/1000);
• very rare (< 1/10000);
• frequency unknown (the frequency of occurrence of events cannot be determined based on available data).

Gastrointestinal disorders:
• often: diarrhea, abdominal pain;
• frequency unknown: nausea, vomiting.

Respiratory system disorders:
• often: cough;
• uncommon: shortness of breath.

Skin and subcutaneous tissue disorders:
• often: rash;
• frequency unknown: urticaria, angioedema.

Immune system disorders:
• uncommon: hypersensitivity reactions (erythematous rash, generalized rash, erythema, edema, eyelid edema, facial edema, peripheral edema, swelling, facial swelling, itching, generalized itching).

Nervous system disorders:
• frequency unknown: headache.

General disorders:
• frequency unknown: fever, fatigue.

Interaction

The drug can be used simultaneously with other drugs, including antibiotics.

Overdose

There are no reports of intoxication due to drug overdose. The composition of the drug Broncho-Munal® and the results of studying its toxicity in animals indicate that an overdose is unlikely.

Short product description

Broncho-Munal – a comprehensive system for fighting colds!

The immunostimulator Broncho-Munal® is used in children over 12 years of age and adults.

Proven benefits:
• helps strengthen the immune system in a natural (physiological) way;
• fights not only viruses – the cause of colds, but also bacteria – the cause of complications;
• helps reduce the duration of the disease;
• reduces the need for antibiotics;
• reduces the incidence of ARVI (“acute respiratory viral infection”) by 36% during the year;
• helps reduce the risk of complications.

The drug can be used at any stage in the complex treatment of acute respiratory viral infections and colds.

To boost immunity, take 1 capsule 30 minutes before meals, 1 time per day:
• in the complex treatment of respiratory infections – until symptoms disappear (fever, runny nose, cough, etc.), but not less than 10 days.
• for the prevention of recurrent acute respiratory viral infections – three courses of 10 days each with an interval of 20 days between courses.

A serious danger of ARVI and colds is the rapid reproduction of viruses, their ability to be instantly transmitted from person to person and possible bacterial complications – bronchitis, sinusitis, otitis. It is important to block the proliferation of viruses in the body and not prolong a cold.

The immunomodulator Broncho-Munal® is used in the complex treatment of acute and prevention of recurrent respiratory tract infections and exacerbation of chronic bronchitis.

Prescribing

For children over 12 years old, for adults

Storage conditions

At temperatures from 15 ◦C to 25 ◦C.
Keep out of the reach of children.

Shelf life

5 years.
Do not use the drug after the expiration date.

Manufacturer

Lek d.d., Slovenia